Anavex Life Sciences Corp (AVXL)

[gbrown6332]

The FDA approved Namenda for the treatment of AD in 2003. Twenty years with no notable medical breakthroughs. We believers in the medical promise of Blarcamesine should take comfort in the FDA's willingness, if not mild desperation, reflected in their recent approvals of suboptimal and alarming AD mAb medical applications. Lilly is poised to add to the mAb off ramp.

Our blockbuster AD solution has proven to be both safe and effective. The FDA should welcome our petition for commercial approval, breaking a 20 year AD medical losing streak, with unbridled joy.

I tend to agree, once 2-73 is approved for patient use, any additional parallel trial requirement by the FDA, whatever the semantics, will be largely symbolic.